International Urology and Nephrology

, Volume 48, Issue 5, pp 817–818 | Cite as

Eculizumab for the treatment of atypical hemolytic uremic syndrome recurrence after kidney transplantation associated with complement factor H mutations: a case report with a 5-year follow-up

  • Masayoshi Okumi
  • Kazuya Omoto
  • Kohei Unagami
  • Hideki Ishida
  • Kazunari Tanabe
Nephrology - Letter to the editor

References

  1. 1.
    Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C (2011) New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 7(1):23–35. doi:10.1038/nrneph.2010.155 CrossRefPubMedGoogle Scholar
  2. 2.
    Ponticelli C, Banfi G (2006) Thrombotic microangiopathy after kidney transplantation. Transpl Int 19(10):789–794. doi:10.1111/j.1432-2277.2006.00354.x CrossRefPubMedGoogle Scholar
  3. 3.
    Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361(17):1676–1687. doi:10.1056/NEJMra0902814 CrossRefPubMedGoogle Scholar
  4. 4.
    Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A et al (2012) Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 12(12):3337–3354. doi:10.1111/j.1600-6143.2012.04252.x CrossRefPubMedGoogle Scholar
  5. 5.
    Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M et al (2008) Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 8(8):1694–1701. doi:10.1111/j.1600-6143.2008.02297.x CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Masayoshi Okumi
    • 1
  • Kazuya Omoto
    • 1
  • Kohei Unagami
    • 2
  • Hideki Ishida
    • 1
  • Kazunari Tanabe
    • 1
  1. 1.Department of Urology, Kidney CenterTokyo Women’s Medical UniversityTokyoJapan
  2. 2.Department of Internal Medicine, Kidney CenterTokyo Women’s Medical UniversityTokyoJapan

Personalised recommendations